Study to Characterize Puffing Topography With Use of JUUL Electronic Nicotine Delivery Systems (ENDS) in Adult, Closed-System ENDS Consumers

NCT04088175 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2021-06-14

No results posted yet for this study

Summary

A randomized, open label, 2-group, 4-period cross-over study in adult closed system ENDS consumers designed to evaluate puff topography parameters with use of JUUL ENDS products (Virginia Tobacco, Menthol, Mint, and Mango flavors, each at 5% and 3% nicotine strengths).

Conditions

  • Electronic Cigarette Use

Interventions

OTHER

JUUL ENDS - Virginia Tobacco 5% nicotine strength

JUUL ENDS - Virginia Tobacco 5% nicotine strength

OTHER

JUUL ENDS - Virginia Tobacco 3% nicotine strength

JUUL ENDS - Virginia Tobacco 3% nicotine strength

OTHER

JUUL ENDS - Menthol 5% nicotine strength

JUUL ENDS - Menthol 5% nicotine strength

OTHER

JUUL ENDS - Menthol 3% nicotine strength

JUUL ENDS - Menthol 3% nicotine strength

OTHER

JUUL ENDS - Mint 5% nicotine strength

JUUL ENDS - Mint 5% nicotine strength

OTHER

JUUL ENDS - Mint 3% nicotine strength

JUUL ENDS - Mint 3% nicotine strength

OTHER

JUUL ENDS - Mango 5% nicotine strength

JUUL ENDS - Mango 5% nicotine strength

OTHER

JUUL ENDS - Mango 3% nicotine strength

JUUL ENDS - Mango 3% nicotine strength

Sponsors & Collaborators

  • Los Angeles Clinical Trials

    collaborator UNKNOWN
  • Battelle Memorial Institute

    collaborator OTHER
  • Juul Labs, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2020-01-23
Completion
2020-01-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088175 on ClinicalTrials.gov